{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06333652",
            "orgStudyIdInfo": {
                "id": "22-009239"
            },
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders",
            "officialTitle": "Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders",
            "therapeuticArea": [
                "Other"
            ],
            "study": "ravulizumab-in-pregnancies-complicated-by-severe-hypertensive-disorders"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-09-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-20",
            "studyFirstSubmitQcDate": "2024-03-20",
            "studyFirstPostDateStruct": {
                "date": "2024-03-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-21",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Maria Lourdes Gonzalez Suarez",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome."
        },
        "conditionsModule": {
            "conditions": [
                "Preeclampsia"
            ],
            "keywords": [
                "Hemolysis",
                "Elevated Liver enzymes",
                "Low Platelets"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 14,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Revulizumab Treatment",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects will receive an single-dose infusion of Ravulizumab.",
                    "interventionNames": [
                        "Drug: Ravulizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ravulizumab",
                    "description": "Intravenous infusion 100 mg/ml",
                    "armGroupLabels": [
                        "Revulizumab Treatment"
                    ],
                    "otherNames": [
                        "Ultomiris"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Alternative Complement Pathway Biomarkers at time of delivery",
                    "description": "Concentration in serum of biomarkers: sMAC, Bb, and C5 at time of delivery",
                    "timeFrame": "Baseline"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pregnancy duration",
                    "description": "Length of pregnancy measured in number of weeks.",
                    "timeFrame": "Approximately 40 weeks"
                },
                {
                    "measure": "Clinical biomarkers of severe features of preeclampsia and HELLP syndrome",
                    "description": "Concentration of clinical biomarkers in serum: creatinine, AST, ALT, LDH and platelets",
                    "timeFrame": "72 hours after Ravulizumab infusion"
                },
                {
                    "measure": "Hospitalization length in the postpartum period",
                    "description": "Length of hospital stay measured in number of days in hospital stay (peripartum period)",
                    "timeFrame": "Approximately 3-5 days, it may vary"
                },
                {
                    "measure": "Meningococcal infection after use of ravulizumab",
                    "description": "Number of participants to present a meningococcal infection after use of Ravulizumab",
                    "timeFrame": "72 hours up to 3 weeks after Ravulizumab infusion"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Individuals with \\< 34 0/7 weeks of gestation.\n* Individuals with severe preeclampsia or HELLP features.\n\nExclusion Criteria:\n\n* Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).\n* Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "maximumAge": "50 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Maria Lourdes Gonzalez Suarez, MD, PhD",
                    "affiliation": "Mayo Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic Minnesota",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Maria L. Gonzalez Suarez, MD,PhD",
                            "role": "CONTACT",
                            "phone": "507-284-4083",
                            "email": "gonzalezsuarez.maria@mayo.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011225",
                    "term": "Pre-Eclampsia"
                },
                {
                    "id": "D000006973",
                    "term": "Hypertension"
                }
            ],
            "ancestors": [
                {
                    "id": "D000046110",
                    "term": "Hypertension, Pregnancy-Induced"
                },
                {
                    "id": "D000011248",
                    "term": "Pregnancy Complications"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10024",
                    "name": "Hypertension",
                    "asFound": "Hypertensive Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14106",
                    "name": "Pre-Eclampsia",
                    "asFound": "Preeclampsia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9547",
                    "name": "Hemolysis",
                    "relevance": "LOW"
                },
                {
                    "id": "M7633",
                    "name": "Eclampsia",
                    "relevance": "LOW"
                },
                {
                    "id": "M25635",
                    "name": "Hypertension, Pregnancy-Induced",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T2019",
                    "name": "Eclampsia",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000629409",
                    "term": "Ravulizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000051056",
                    "term": "Complement Inactivating Agents"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                },
                {
                    "id": "M287455",
                    "name": "Ravulizumab",
                    "asFound": "CCT",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6392",
                    "name": "Complement System Proteins",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}